Cargando…
P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430131/ http://dx.doi.org/10.1097/01.HS9.0000847372.57687.d4 |
| _version_ | 1784779668336934912 |
|---|---|
| author | Matasar, M. Bartlett, N. L. Sehn, L. H. Schuster, S. J. Assouline, S. Giri, P. Kuruvilla, J. Canales, M. Dietrich, S. Fay, K. Ku, M. Nastoupil, L. J. Wei, M. C. Yin, S. To, I. Turner, D. Huang, H. Min, J. Penuel, E. Budde, L. E. |
| author_facet | Matasar, M. Bartlett, N. L. Sehn, L. H. Schuster, S. J. Assouline, S. Giri, P. Kuruvilla, J. Canales, M. Dietrich, S. Fay, K. Ku, M. Nastoupil, L. J. Wei, M. C. Yin, S. To, I. Turner, D. Huang, H. Min, J. Penuel, E. Budde, L. E. |
| author_sort | Matasar, M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430131 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94301312022-08-31 P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY Matasar, M. Bartlett, N. L. Sehn, L. H. Schuster, S. J. Assouline, S. Giri, P. Kuruvilla, J. Canales, M. Dietrich, S. Fay, K. Ku, M. Nastoupil, L. J. Wei, M. C. Yin, S. To, I. Turner, D. Huang, H. Min, J. Penuel, E. Budde, L. E. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430131/ http://dx.doi.org/10.1097/01.HS9.0000847372.57687.d4 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Matasar, M. Bartlett, N. L. Sehn, L. H. Schuster, S. J. Assouline, S. Giri, P. Kuruvilla, J. Canales, M. Dietrich, S. Fay, K. Ku, M. Nastoupil, L. J. Wei, M. C. Yin, S. To, I. Turner, D. Huang, H. Min, J. Penuel, E. Budde, L. E. P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY |
| title | P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY |
| title_full | P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY |
| title_fullStr | P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY |
| title_full_unstemmed | P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY |
| title_short | P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY |
| title_sort | p1126: mosunetuzumab is efficacious and well tolerated in patients aged <65 and ≥65 years with relapsed/refractory follicular lymphoma and ≥2 prior therapies: subgroup analysis of a pivotal phase ii study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430131/ http://dx.doi.org/10.1097/01.HS9.0000847372.57687.d4 |
| work_keys_str_mv | AT matasarm p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT bartlettnl p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT sehnlh p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT schustersj p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT assoulines p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT girip p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT kuruvillaj p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT canalesm p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT dietrichs p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT fayk p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT kum p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT nastoupillj p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT weimc p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT yins p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT toi p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT turnerd p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT huangh p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT minj p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT penuele p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT buddele p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy |